Olink intends to make the Olink Explore 3072 high quality protein assay platform broadly available in the fourth quarter of 2021. The purpose of understanding the genetics of disease is to use that information to create new means of diagnosing, treating and preventing disease. Using its unique expertise and population resources, deCODE genetics has discovered key genetic risk factors for dozens of common diseases ranging from cardiovascular disease to cancer.

We see deCODE genetics as an exceptional early-access site for the Olink Explore 3072 platform.”īased in Reykjavik, Iceland, deCODE genetics is a global leader in analyzing and understanding the human genome. We believe this agreement demonstrates the accelerating trend to continue to connect the wealth of available genomic data with actionable proteomics. “They have a very impressive track record of providing insights to enhance the vital research into the most common and life-threatening diseases. “We are proud to work closely with deCODE genetics’ world-class genomic and pharmaceutical scientists,” said Jon Heimer, CEO of Olink. In doing so, deCODE and Olink will work together to optimize Olink’s high throughput, high-quality proteomics to its population scale efforts of advancing modern healthcare. Through an agreement between the two companies, deCODE genetics will be one of the first companies to adopt and internalize the new Explore 3072 proteomics platform and will act as an early testing site for its use.

UPPSALA, Sweden, J(GLOBE NEWSWIRE) - Olink Holding AB (publ) (Nasdaq: OLK) today announced that deCODE genetics, a global leader in analyzing and understanding the human genome, will have internal access to the Olink® Explore 3072 platform, comprised of approximately 3,000 high quality protein assays with a Next Generation Sequencing (NGS) read-out.

Decode genetics stocks yahoo